SBHMY
Price:
$8.335
Market Cap:
$55.68B
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan ...[Read more]
Industry
Biotechnology
IPO Date
2017-09-05
Stock Exchange
PNK
Ticker
SBHMY
According to Sino Biopharmaceutical Limited’s latest financial reports and current stock price. The company's current ROE is 11.52%. This represents a change of 401.54% compared to the average of 2.30% of the last 4 quarters.
The mean historical ROE of Sino Biopharmaceutical Limited over the last ten years is 23.56%. The current 11.52% ROE has changed -51.11% with respect to the historical average. Over the past ten years (40 quarters), SBHMY's ROE was at its highest in in the June 2021 quarter at 26.72%. The ROE was at its lowest in in the December 2022 quarter at -0.58%.
Average
23.56%
Median
22.91%
Minimum
7.65%
Maximum
48.23%
Discovering the peaks and valleys of Sino Biopharmaceutical Limited ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 86.07%
Maximum Annual ROE = 48.23%
Minimum Annual Increase = -65.13%
Minimum Annual ROE = 7.65%
Year | ROE | Change |
---|---|---|
2023 | 7.65% | -54.50% |
2022 | 16.82% | -65.13% |
2021 | 48.23% | 86.07% |
2020 | 25.92% | 71.78% |
2019 | 15.09% | -51.27% |
2018 | 30.97% | 31.36% |
2017 | 23.57% | 9.47% |
2016 | 21.53% | -6.10% |
2015 | 22.93% | 0.19% |
2014 | 22.89% | 21.15% |
The current ROE of Sino Biopharmaceutical Limited (SBHMY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
24.23%
5-year avg
22.74%
10-year avg
23.56%
Sino Biopharmaceutical Limited’s ROE is less than Institute of Biomedical Research Corp. (131.12%), less than Defence Therapeutics Inc. (377.40%), greater than Aileron Therapeutics, Inc. (-46.89%), greater than Enlivex Therapeutics Ltd. (-67.57%), greater than Protagenic Therapeutics, Inc. (-308.96%), less than ZIVO Bioscience, Inc. (618.61%), greater than Cyteir Therapeutics, Inc. (-9.44%), less than Eledon Pharmaceuticals, Inc. (21.51%), less than Opthea Limited (398.06%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Nuvalent, Inc. (-28.63%), greater than Tarsus Pharmaceuticals, Inc. (-55.86%), less than Genfit S.A. (1.77%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Tempest Therapeutics, Inc. (-187.44%), greater than RenovoRx, Inc. (-242.57%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Acurx Pharmaceuticals, Inc. (-67679.28%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than XOMA Corporation (-33.68%), greater than Kezar Life Sciences, Inc. (-59.73%), greater than Longboard Pharmaceuticals, Inc. (-33.03%), less than Entrada Therapeutics, Inc. (16.11%),
Company | ROE | Market cap |
---|---|---|
131.12% | $40.90M | |
377.40% | $12.86M | |
-46.89% | $47.02M | |
-67.57% | $27.05M | |
-308.96% | $3.34M | |
618.61% | $78.37M | |
-9.44% | $108.71M | |
21.51% | $255.09M | |
398.06% | $4.47B | |
-52.22% | $2.23B | |
-28.63% | $5.87B | |
-55.86% | $2.07B | |
1.77% | $183.01M | |
-184.40% | $42.01M | |
-187.44% | $37.39M | |
-242.57% | $30.96M | |
-47.95% | $193.98M | |
-67679.28% | $14.78M | |
31.99% | $169.78M | |
-33.68% | $319.66M | |
-59.73% | $47.86M | |
-33.03% | $2.34B | |
16.11% | $657.09M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sino Biopharmaceutical Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sino Biopharmaceutical Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Sino Biopharmaceutical Limited's ROE?
How is the ROE calculated for Sino Biopharmaceutical Limited (SBHMY)?
What is the highest ROE for Sino Biopharmaceutical Limited (SBHMY)?
What is the 3-year average ROE for Sino Biopharmaceutical Limited (SBHMY)?
What is the 5-year average ROE for Sino Biopharmaceutical Limited (SBHMY)?
How does the current ROE for Sino Biopharmaceutical Limited (SBHMY) compare to its historical average?